Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Analysis of the p53 pathway in clear cell renal cell carcinoma to identify novel drug combinations.

Boyd MT, Ahmed-Ebbiary A, Polanski R, Noon A, Parsons K, Rubbi CP, Vlatkovic N.

J Clin Oncol. 2012 Feb 10;30(5_suppl):460. doi: 10.1200/jco.2012.30.5_suppl.460.

PMID:
28143092
2.

Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.

Oughton JB, Poad H, Twiddy M, Collinson M, Hiley V, Gordon K, Johnson M, Jain S, Noon AP, Chahal R, Simms M, Dooldeniya M, Koenig P, Goodwin L, Brown JM, Catto JWF; BRAVO study group.

BMJ Open. 2017 Aug 11;7(8):e017913. doi: 10.1136/bmjopen-2017-017913.

3.

Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy.

Pang KH, Groves R, Venugopal S, Noon AP, Catto JWF.

Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30660-7. doi: 10.1016/j.eururo.2017.07.031. [Epub ahead of print]

PMID:
28801130
4.

Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence.

Noon AP, Martinsen JI, Catto JWF, Pukkala E.

Eur Urol Focus. 2016 Jul 20. pii: S2405-4569(16)30093-1. doi: 10.1016/j.euf.2016.06.014. [Epub ahead of print]

PMID:
28753772
5.

Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.

Aziz A, Dobruch J, Hendricksen K, Kluth LA, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, Shariat SF, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.

World J Urol. 2017 Jan 10. doi: 10.1007/s00345-016-1995-z. [Epub ahead of print] Review.

PMID:
28074261
6.

Re: The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial.

Young MJ, Noon AP.

Eur Urol. 2017 Apr;71(4):690-691. doi: 10.1016/j.eururo.2016.11.013. Epub 2016 Nov 30. No abstract available.

PMID:
27914900
7.

Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.

Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA.

Eur Urol. 2016 Feb;69(2):300-10. doi: 10.1016/j.eururo.2015.08.037. Epub 2015 Sep 4. Review.

PMID:
26346676
8.

ZFP57 and the Targeted Maintenance of Postfertilization Genomic Imprints.

Takahashi N, Gray D, Strogantsev R, Noon A, Delahaye C, Skarnes WC, Tate PH, Ferguson-Smith AC.

Cold Spring Harb Symp Quant Biol. 2015;80:177-87. doi: 10.1101/sqb.2015.80.027466. Review.

PMID:
27325708
9.

Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer.

Liu Y, Noon AP, Aguiar Cabeza E, Shen J, Kuk C, Ilczynski C, Ni R, Sukhu B, Chan K, Barbosa-Morais NL, Hermanns T, Blencowe BJ, Azad A, van der Kwast TH, Catto JW, Zlotta AR, Wrana JL.

Eur Urol. 2014 Dec;66(6):982-6. doi: 10.1016/j.eururo.2014.07.045. Epub 2014 Sep 6.

PMID:
25199720
10.

Identification of differentially expressed long noncoding RNAs in bladder cancer.

Peter S, Borkowska E, Drayton RM, Rakhit CP, Noon A, Chen W, Catto JW.

Clin Cancer Res. 2014 Oct 15;20(20):5311-21. doi: 10.1158/1078-0432.CCR-14-0706. Epub 2014 Aug 27.

11.

Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.

Polański R, Noon AP, Blaydes J, Phillips A, Rubbi CP, Parsons K, Vlatković N, Boyd MT.

Cancer Lett. 2014 Oct 28;353(2):211-9. doi: 10.1016/j.canlet.2014.07.024. Epub 2014 Jul 24.

PMID:
25067787
12.

Noncoding RNA in bladder cancer: a specific focus upon high-risk nonmuscle invasive disease.

Noon AP, Catto JW.

Curr Opin Urol. 2014 Sep;24(5):506-11. doi: 10.1097/MOU.0000000000000090. Review.

PMID:
25051024
13.

Family context and externalizing correlates of childhood animal cruelty in adjudicated delinquents.

Walters GD, Noon A.

J Interpers Violence. 2015 May;30(8):1369-86. doi: 10.1177/0886260514540328. Epub 2014 Jul 1.

PMID:
24986192
14.

Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.

Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MA, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS.

Br J Cancer. 2014 Jul 29;111(3):444-51. doi: 10.1038/bjc.2014.305. Epub 2014 Jun 10.

15.

All bacillus Calmette-Guérin (BCG) strains are equal, but some BCG strains are more equal than others.

Noon AP, Kulkarni GS.

Eur Urol. 2014 Oct;66(4):689-91. doi: 10.1016/j.eururo.2014.04.008. Epub 2014 Apr 28. No abstract available.

PMID:
24792643
16.

Urothelial Bladder Cancer Urinary Biomarkers.

Noon AP, Zlotta AR.

EJIFCC. 2014 Apr 28;25(1):99-114. eCollection 2014 Apr.

17.

The cognitive processes underpinning clinical decision in triage assessment: a theoretical conundrum?

Noon AJ.

Int Emerg Nurs. 2014 Jan;22(1):40-6. doi: 10.1016/j.ienj.2013.01.003. Epub 2013 May 17.

PMID:
23685041
18.

Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients.

Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW.

Br J Cancer. 2013 Apr 16;108(7):1534-40. doi: 10.1038/bjc.2013.106. Epub 2013 Mar 12.

19.

Bladder cancer in 2012: Challenging current paradigms.

Noon AP, Catto JW.

Nat Rev Urol. 2013 Feb;10(2):67-8. doi: 10.1038/nrurol.2012.252. Epub 2013 Jan 8. Review. No abstract available.

PMID:
23295237
20.

Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.

Thomas F, Noon AP, Rubin N, Goepel JR, Catto JW.

Eur Urol. 2013 Jan;63(1):145-54. doi: 10.1016/j.eururo.2012.08.064. Epub 2012 Sep 5.

PMID:
22985746

Supplemental Content

Support Center